Mp08-07 Effects of Neoadjuvant Chemotherapy on Rates of Depression in Muscle Invasive Bladder Cancer

You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation I (MP08)1 May 2024MP08-07 EFFECTS OF NEOADJUVANT CHEMOTHERAPY ON RATES OF DEPRESSION IN MUSCLE INVASIVE BLADDER CANCER Matthew R. DeSanto, Frank Anne, Stacie Deslich, Nathan Hale, Thomas Cato, and Clayton Davis Matthew R. DeSantoMatthew R. DeSanto , Frank AnneFrank Anne , Stacie DeslichStacie Deslich , Nathan HaleNathan Hale , Thomas CatoThomas Cato , and Clayton DavisClayton Davis View All Author Informationhttps://doi.org/10.1097/01.JU.0001008780.87855.57.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The objective of this large retrospective cohort study is to better understand the relationship of bladder cancer and depression incidence, specifically relating to the incorporation of neoadjuvant chemotherapy in treatment plans. METHODS: This is a large retrospective cohort study utilizing a formulated dataset from the TriNetX Research Network Database. A search query was performed and designed in consultation with the TriNetX analysts across participating health care organizations within the TriNetX research network. ICD-10 codes relating to bladder cancer and depression diagnoses and treatments were implemented to identify patients of interest. Propensity score matching was performed to control for various demographic factors and comorbidities. The patient population was limited to stage T2 bladder cancer, and neoadjuvant chemotherapy was defined as receiving chemotherapy within 90 days prior to cystectomy. The primary outcome was denoted as diagnosis of depressive episode within 3 months of therapy and secondary outcomes of hospitalizations, mortality, and suicide attempts within 3 months of therapy were analyzed. RESULTS: A total of 4630 patients were included after propensity score matching, yielding 2315 patients in each group. All patients had T2 disease, and all patients underwent cystectomy. In the cohort who received neoadjuvant chemotherapy, 243 (10.5%) patients had obtained a diagnosis of depression within three months from cystectomy compared to 144 (6.2%) patients who did not receive neoadjuvant chemotherapy (95% CI [0.027; 0.059]; p<0.001). Odds ratio was 1.768 (95% CI [1.426, 2.192]) when comparing cohorts of with and without neoadjuvant chemotherapy. There was no statistical difference in mortality (95% CI [-0.012, 0.014]; p=0.844) or inpatient hospitalizations [95% CI [-0.046, 0.009]; p=0.191) within 3 months. There was a statistically significant increase in suicide attempts in the neoadjuvant chemotherapy group within 3 months from cystectomy (95% CI [0.002, 0.007]; p=0.002]. CONCLUSIONS: Bladder cancer development with or without treatment can induce significant patient morbidity with ensuing depression. Our retrospective cohort study demonstrates neoadjuvant chemotherapy correlates to increased incidence of depression as well as suicidal attempts. Meticulous attention needs to be directed towards mental health counseling and treatment for oncologic patients. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e116 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Matthew R. DeSanto More articles by this author Frank Anne More articles by this author Stacie Deslich More articles by this author Nathan Hale More articles by this author Thomas Cato More articles by this author Clayton Davis More articles by this author Expand All Advertisement PDF downloadLoading ...